Insight

Paolo Tarantino Presented DATO-Base Trial Poster at ASCO 2025 on Breast Cancer CNS Metastases

Paolo Tarantino/X

Jun 3, 2025, 16:58

Paolo Tarantino Presented DATO-Base Trial Poster at ASCO 2025 on Breast Cancer CNS Metastases

Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared on X by Dana-Farber’s Breast Oncology Center, adding:

“Patients with CNS disease need more. Need better therapies. Like novel ADCs!

DATO-Base is the first trial I designed when I moved to DFCI, mentored by Dr Sarah Sammons and Nancy Lin.

It tests Dato-DXd for CNS disease, with the LMD cohort fully accrued.

Results coming soon – stay tuned!”

Quoting Dana-Farber’s Breast Oncology Center‘s post:

“ASCO 2025 Poster Session on MBC DATO Base: A phase II study of Datopotamab deruxtecan for patients with Breast Cancer Brain Metastases or Leptomeningeal disease.”

DATO-Base

More posts featuring Paolo Tarantino on OncoDaily.

ASCO ASCO 2025 ASCO25 Breast Cancer Breast Cancer Brain Metastases cancer CNS Dana-Farber Cancer Institute Dana-Farber’s Breast Oncology Center Dato-DXd datopotamab Deruxtecan Harvard Medical School Leptomeningeal Disease LMD Nancy Lin OncoDaily Oncology Paolo Tarantino Sarah Sammons

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment

15 Posts Not to Miss from the 2nd Day of ASCO 2025